These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 27775461)
1. Effect of a treat-to-target strategy based on methotrexate and intra-articular betamethasone with or without additional cyclosporin on MRI-assessed synovitis, osteitis, tenosynovitis, bone erosion, and joint space narrowing in early rheumatoid arthritis: results from a 2-year randomized double-blind placebo-controlled trial (CIMESTRA). Møller-Bisgaard S; Ejbjerg BJ; Eshed I; Hørslev-Petersen K; Hetland ML; Jurik AG; Thomsen H; Torfing T; Stengaard-Pedersen K; Junker P; Krogh NS; Lottenburger T; Ellingsen T; Andersen LS; Skjødt H; Svendsen AJ; Tarp U; Hansen IT; Pødenphant J; Pedersen JK; Lindegaard H; Hanson LG; Vestergaard A; Glinatsi D; Østergaard M Scand J Rheumatol; 2017 Sep; 46(5):335-345. PubMed ID: 27775461 [TBL] [Abstract][Full Text] [Related]
2. A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial. Axelsen MB; Eshed I; Hørslev-Petersen K; Stengaard-Pedersen K; Hetland ML; Møller J; Junker P; Pødenphant J; Schlemmer A; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Dam MY; Hansen I; Horn HC; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Krogh NS; Johansen JS; Østergaard M; Ann Rheum Dis; 2015 May; 74(5):867-75. PubMed ID: 24412895 [TBL] [Abstract][Full Text] [Related]
3. Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: a magnetic resonance imaging study of 318 methotrexate-naive rheumatoid arthritis patients. Østergaard M; Emery P; Conaghan PG; Fleischmann R; Hsia EC; Xu W; Rahman MU Arthritis Rheum; 2011 Dec; 63(12):3712-22. PubMed ID: 22127693 [TBL] [Abstract][Full Text] [Related]
4. Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques. Conaghan PG; Østergaard M; Bowes MA; Wu C; Fuerst T; van der Heijde D; Irazoque-Palazuelos F; Soto-Raices O; Hrycaj P; Xie Z; Zhang R; Wyman BT; Bradley JD; Soma K; Wilkinson B Ann Rheum Dis; 2016 Jun; 75(6):1024-33. PubMed ID: 27002108 [TBL] [Abstract][Full Text] [Related]
5. The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy. Conaghan PG; Peterfy C; Olech E; Kaine J; Ridley D; Dicarlo J; Friedman J; Devenport J; Troum O Ann Rheum Dis; 2014 May; 73(5):810-6. PubMed ID: 24525910 [TBL] [Abstract][Full Text] [Related]
6. Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Hetland ML; Stengaard-Pedersen K; Junker P; Lottenburger T; Ellingsen T; Andersen LS; Hansen I; Skjødt H; Pedersen JK; Lauridsen UB; Svendsen A; Tarp U; Pødenphant J; Hansen G; Lindegaard H; de Carvalho A; Østergaard M; Hørslev-Petersen K; Arthritis Rheum; 2006 May; 54(5):1401-9. PubMed ID: 16645967 [TBL] [Abstract][Full Text] [Related]
7. Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial. Jensen TW; Hansen MS; Hørslev-Petersen K; Hyldstrup L; Abrahamsen B; Langdahl B; Zerahn B; Pødenphant J; Stengaard-Petersen K; Junker P; Østergaard M; Lottenburger T; Ellingsen T; Andersen LS; Hansen I; Skjødt H; Pedersen JK; Lauridsen UB; Svendsen AJ; Tarp U; Lindegaard H; Jurik AG; Vestergaard A; Hetland ML; Ann Rheum Dis; 2014 Jun; 73(6):1123-9. PubMed ID: 23661492 [TBL] [Abstract][Full Text] [Related]
8. Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial. Conaghan PG; Durez P; Alten RE; Burmester GR; Tak PP; Klareskog L; Catrina AI; DiCarlo J; Gaillez C; Le Bars M; Zhou X; Peterfy C Ann Rheum Dis; 2013 Aug; 72(8):1287-94. PubMed ID: 22915624 [TBL] [Abstract][Full Text] [Related]
9. Magnetic Resonance Imaging (MRI) Results Following Discontinuation of Methotrexate in Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: The COMP-ACT MRI Substudy. Peterfy C; Kremer J; Rigby W; Singer N; Birchwood C; Gill D; Reiss W; Pei J; Michalska M J Rheumatol; 2020 Mar; 47(3):325-332. PubMed ID: 31154414 [TBL] [Abstract][Full Text] [Related]
10. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Quinn MA; Conaghan PG; O'Connor PJ; Karim Z; Greenstein A; Brown A; Brown C; Fraser A; Jarret S; Emery P Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102 [TBL] [Abstract][Full Text] [Related]
11. MRI assessment of early response to certolizumab pegol in rheumatoid arthritis: a randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16. Østergaard M; Jacobsson LT; Schaufelberger C; Hansen MS; Bijlsma JW; Dudek A; Rell-Bakalarska M; Staelens F; Haake R; Sundman-Engberg B; Bliddal H Ann Rheum Dis; 2015 Jun; 74(6):1156-63. PubMed ID: 25512675 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of abatacept in patients with rheumatoid arthritis, as assessed by magnetic resonance imaging of bilateral hands. Kukida Y; Kasahara A; Seno T; Inoue T; Sagawa R; Kida T; Nakabayashi A; Nagahara H; Murakami K; Sugitani T; Morita S; Ito H; Oda R; Fujiwara H; Kohno M; Kawahito Y Int J Rheum Dis; 2018 Sep; 21(9):1678-1685. PubMed ID: 28730687 [TBL] [Abstract][Full Text] [Related]
13. Magnetic resonance imaging assessed inflammation in the wrist is associated with patient-reported physical impairment, global assessment of disease activity and pain in early rheumatoid arthritis: longitudinal results from two randomised controlled trials. Glinatsi D; Baker JF; Hetland ML; Hørslev-Petersen K; Ejbjerg BJ; Stengaard-Pedersen K; Junker P; Ellingsen T; Lindegaard HM; Hansen I; Lottenburger T; Møller JM; Ørnbjerg L; Vestergaard A; Jurik AG; Thomsen HS; Torfing T; Møller-Bisgaard S; Axelsen MB; Østergaard M Ann Rheum Dis; 2017 Oct; 76(10):1707-1715. PubMed ID: 28611080 [TBL] [Abstract][Full Text] [Related]
14. Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial. Conaghan PG; Emery P; Østergaard M; Keystone EC; Genovese MC; Hsia EC; Xu W; Rahman MU Ann Rheum Dis; 2011 Nov; 70(11):1968-74. PubMed ID: 21784729 [TBL] [Abstract][Full Text] [Related]
15. Radiographic progression and remission rates in early rheumatoid arthritis - MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial. Hetland ML; Stengaard-Pedersen K; Junker P; Østergaard M; Ejbjerg BJ; Jacobsen S; Lottenburger T; Hansen I; Tarp U; Andersen LS; Svendsen A; Pedersen JK; Lauridsen UB; Ellingsen T; Lindegaard H; Pødenphant J; Vestergaard A; Jurik AG; Hørslev-Petersen K; Ann Rheum Dis; 2010 Oct; 69(10):1789-95. PubMed ID: 20444751 [TBL] [Abstract][Full Text] [Related]
16. Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study. Hetland ML; Stengaard-Pedersen K; Junker P; Lottenburger T; Hansen I; Andersen LS; Tarp U; Svendsen A; Pedersen JK; Skjødt H; Lauridsen UB; Ellingsen T; Hansen GV; Lindegaard H; Vestergaard A; Jurik AG; Østergaard M; Hørslev-Petersen K; Ann Rheum Dis; 2008 Jun; 67(6):815-22. PubMed ID: 17878209 [TBL] [Abstract][Full Text] [Related]
17. The CIMESTRA study: intra-articular glucocorticosteroids and synthetic DMARDs in a treat-to-target strategy in early rheumatoid arhtritis. Hetland ML; Hørslev-Petersen K Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S44-9. PubMed ID: 23079125 [TBL] [Abstract][Full Text] [Related]
18. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA). Hetland ML; Ejbjerg B; Hørslev-Petersen K; Jacobsen S; Vestergaard A; Jurik AG; Stengaard-Pedersen K; Junker P; Lottenburger T; Hansen I; Andersen LS; Tarp U; Skjødt H; Pedersen JK; Majgaard O; Svendsen AJ; Ellingsen T; Lindegaard H; Christensen AF; Vallø J; Torfing T; Narvestad E; Thomsen HS; Ostergaard M; Ann Rheum Dis; 2009 Mar; 68(3):384-90. PubMed ID: 18388160 [TBL] [Abstract][Full Text] [Related]
19. Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis. Conaghan PG; Østergaard M; Troum O; Bowes MA; Guillard G; Wilkinson B; Xie Z; Andrews J; Stein A; Chapman D; Koenig A Arthritis Res Ther; 2019 Oct; 21(1):214. PubMed ID: 31639034 [TBL] [Abstract][Full Text] [Related]
20. Effect of very early treatment in rheumatoid arthritis on bone oedema and synovitis, using magnetic resonance imaging. Kosta PE; Voulgari PV; Zikou AK; Tsampoulas K; Drosos AA; Argyropoulou MI Scand J Rheumatol; 2012 Oct; 41(5):339-44. PubMed ID: 22646866 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]